Literature DB >> 27288787

Can we differentiate between herpes simplex encephalitis and Japanese encephalitis?

Jayantee Kalita1, Usha Kant Misra2, Vinita Elizabeth Mani1, Sanjeev Kumar Bhoi1.   

Abstract

BACKGROUND: Herpes simplex encephalitis (HSE) occurs without regional and seasonal predilections. HSE is important to differentiate from arboviral encephalitis in endemic areas because of therapeutic potential of HSE. This study evaluates clinical features, MRI and laboratory findings which may help in differentiating HSE from Japanese encephalitis (JE).
METHODS: Confirmed patients with JE and HSE in last 10years were included. The presenting clinical symptoms including demographic information, seizure, behavioral abnormality, focal weakness and movement disorders were noted. Cranial MRI was done and location and nature of signal alteration were noted. Electroencephalography (EEG), cerebrospinal fluid (CSF), blood counts and serum chemistry were done. Outcome was measured by modified Rankin Scale (mRS). Death, functional outcome and neurological sequelae were noted at 3, 6 and 12months follow up, and compared between HSE and JE. Outcome was categorized as poor (mRS;>2) and good (mRS≤2).
RESULTS: 97 patients with JE and 40 HSE were included. JE patients were younger than HSE and occurred in post monsoon period whereas HSE occurred throughout the year. Seizure (86% vs 40%) and behavioral abnormality (48% vs 10%) were commoner in HSE; whereas movement disorders (76% vs 0%) and focal reflex loss (42% vs 10%) were commoner in JE. CSF findings and laboratory parameters were similar in both the groups. Thalamic involvement in JE and temporal involvement in HSE were specific markers of respective encephalitis. Delta slowing on EEG was more frequent in JE than HSE. 20% JE and 30% HSE died in the hospital, and at 1year follow up JE patients showed better outcome compared to HSE (48% vs 24%). Memory loss (72% vs 22%) was the predominant sequelae in HSE.
CONCLUSION: Seizure and behavioral abnormality are common features in HSE whereas focal reflex loss is commoner in JE. In a patient with acute encephalitis, thalamic lesion suggests JE and temporal lobe involvement HSE. Long term outcome in JE is better compared to HSE.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  EEG; Encephalitis; Herpes simplex encephalitis; Japanese encephalitis; MRI; Outcome

Mesh:

Substances:

Year:  2016        PMID: 27288787     DOI: 10.1016/j.jns.2016.05.017

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  6 in total

1.  Herpes simplex encephalitis with thalamic, brainstem and cerebellar involvement.

Authors:  Meenal Garg; Shilpa Kulkarni; Anaita Udwadia Hegde
Journal:  Neuroradiol J       Date:  2017-06-19

2.  Estimates of Japanese Encephalitis mortality and morbidity: A systematic review and modeling analysis.

Authors:  Yuwei Cheng; Nhat Tran Minh; Quan Tran Minh; Shreya Khandelwal; Hannah E Clapham
Journal:  PLoS Negl Trop Dis       Date:  2022-05-25

Review 3.  Clinical spectrum and management of dystonia in patients with Japanese encephalitis: A systematic review.

Authors:  Roshan Aryal; Suraj Shrestha; Sushan Homagain; Sunit Chhetri; Kshitiz Shrestha; Sanjeev Kharel; Ragesh Karn; Reema Rajbhandari; Bikram Prasad Gajurel; Rajeev Ojha
Journal:  Brain Behav       Date:  2022-01-13       Impact factor: 2.708

4.  Leptomeningeal Enhancement without Thalamic Involvement as an Initial Manifestation of Japanese Encephalitis: A Case Report.

Authors:  Sang Hwa Woo; Ho-Joon Lee; Yeonah Kang
Journal:  Taehan Yongsang Uihakhoe Chi       Date:  2021-02-28

5.  Changing Spectrum of Acute Encephalitis Syndrome in India and a Syndromic Approach.

Authors:  Usha K Misra; Jayantee Kalita
Journal:  Ann Indian Acad Neurol       Date:  2022-06-08       Impact factor: 1.714

Review 6.  Japanese encephalitis - the prospects for new treatments.

Authors:  Lance Turtle; Tom Solomon
Journal:  Nat Rev Neurol       Date:  2018-04-26       Impact factor: 42.937

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.